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Despite the availability of cost-effective prevention strategies, cervical 
cancer remains among the most common cancers worldwide.[1] 
In sub-Saharan Africa, where the vast majority of disease occurs, 
cervical cancer is the leading cause of cancer death among women. [2] 
The relative dearth of organised prevention programmes and a high 
burden of HIV contribute to the region’s high cervical cancer rate. 
Thirteen million women are currently infected with HIV in sub-
Saharan Africa.[3] These women are at significantly increased risk of 
developing a persistent high-risk human papillomavirus infection 
(the necessary cause of most cervical cancers), preinvasive cervical 
disease and invasive cervical cancer (ICC).[4] Cervical disease also 
appears to be harder to treat in HIV-infected women, with lower cure 
rates achieved in this population.[5,6]
South Africa (SA) is home to the largest number of HIV-infected 
individuals in the world,[3] with nearly 60% of incident HIV infections 
occurring in women.[7] The country’s age-standardised incidence of 
cervical cancer is 32 per 100 000,[8] which is one of the highest rates in 
the world. 2010 Southern African HIV Clinicians Society guidelines 
recommend cervical screening with cytology (Pap smears) beginning at 
the time of HIV diagnosis, and at 3-year intervals thereafter for women 
who screen negative. If implemented fully and correctly, this screening 
strategy is expected to reduce women’s lifetime risk of developing 
cervical cancer substantially.[9] However, as in many other low- and 
middle-income countries (LMICs), achieving meaningful cervical 
screening coverage has been elusive. In fact, effective population 
coverage for cervical screening is thought to be <20% in SA.[10] There 
are several reasons for this. First, cancer prevention has not received 
sufficient public policy attention or funding. Second, the cost and 
complex nature of the Pap smear have made cytology-based screening 
difficult to scale up, particularly to rural and remote communities. 
Third, public awareness of and advocacy for cervical cancer prevention 
remain relatively low, resulting in weak demand for services.[11]
Objectives
To estimate the burden of cervical disease among HIV-infected 
women accessing cervical screening services supported through the 
Right to Care Cervical Cancer Prevention Programme, a large donor-
funded public sector programme.
Methods
Design
To estimate the programme-wide burden of cervical disease, we 
developed conditional probability models using parameter estimates 
obtained from both a secondary analysis of routinely collected data 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Estimating the burden of cervical disease among 
HIV-infected women accessing screening services 
in South Africa: A model-based analysis
C J Chibwesha,1,2 MD, MSc, FACOG; B Goeieman,1 MB BCh; S Levin,1 FRCOG; M Mulongo,1 MB BCh; M Faesen,1 FCOG (SA);  
A Swarts,1,3 MSc; S Ramotshela;1,3 S Williams;1 N Rakhombe;1 S Bruce;1 P Michelow,4,5 MB BCh, MSc; C Firnhaber,1,3 MD, MS
1 Right to Care, Helen Joseph Hospital, Johannesburg, South Africa
2  Division of Global Women’s Health, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, 
NC, USA
3  Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the 
Witwatersrand and Helen Joseph Hospital, Johannesburg, South Africa
4  Department of Anatomical Pathology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
5 National Health Laboratory Service, Johannesburg, South Africa
Corresponding author: C J Chibwesha (carla_chibwesha@med.unc.edu)
Background. Cervical cancer remains the second most common cancer among women worldwide, with much of the global burden 
occurring in low- and middle-income countries. HIV-infected women are at increased risk of human papillomavirus infection, preinvasive 
cervical disease and invasive cervical cancer (ICC). Funded through the United States President’s Emergency Plan for AIDS Relief (PEPFAR) 
and working in collaboration with the South African (SA) Department of Health, our team supports cervical screening integrated within 
public sector HIV clinics in SA.
Objectives. To estimate the burden of cervical disease among HIV-infected women accessing screening services supported through our programme.
Methods. We constructed conditional probability models to estimate the burden of grade 1 and grades 2/3 cervical intraepithelial lesions 
(CIN1 and CIN2/3) and ICC among two cohorts: one consisting of 3 190 HIV-infected women for whom only cytology results were 
available for analysis, and another consisting of 75 358 HIV-infected women for whom neither cytology nor histology results were available. 
Parameter estimates for the models were derived from routinely collected programmatic data and published clinical trials.
Results. Between January 2009 and November 2015, 75 358 HIV-infected women underwent Pap smear screening in public sector clinics 
supported by our cervical cancer prevention programme. Based on modelling analysis, we estimate that 46 123 cases of CIN1 (range 45 500 - 
49 608), 13 598 cases of CIN2/3 (range 12 749 - 14 828), and 104 cases of ICC (range 61 - 186) occurred in this population.
Conclusions. Our findings highlight the magnitude of cervical disease among HIV-infected women in SA.
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(described below) and previously published research.[12] We chose to 
model disease burden because patient-level cervical histology data 
are not available from all clinical sites supported by our programme.
Service delivery programme platform
Established in 2009, Right to Care’s Cervical Cancer Prevention 
Programme has provided services to >80 000 women using either 
cytology (n=75 358) or visual inspection with acetic acid (VIA) 
(n=5  532) in Eastern Cape, Free State, Gauteng, Mpumalanga and 
Western Cape provinces. Pap smear screening is typically nurse led, 
with selected rural sites instead performing VIA. Mobile women’s 
health units are employed in under-served areas of the Free State, 
Gauteng, Mpumalanga and Western Cape. These mobile units also 
provide a variety of other reproductive health services (e.g. clinical 
breast examinations, screening for sexually transmitted infections, 
and contraception). Women with abnormal Pap smear or VIA results 
receive follow-up evaluation (i.e. colposcopy) and any clinically 
indicated treatment at either the screening clinic or a referral centre. 
Our team also trains medical officers to perform cervical colposcopy 
and loop electrosurgical excision procedures (LEEPs). Approximately 
23 000 colposcopies and LEEPs have been performed since the 
inception of the programme.
Primary funding for service delivery is provided through the US 
President’s Emergency Plan for AIDS Relief (PEPFAR), and service 
implementation occurs in partnership with the SA Department of 
Health (DoH). Mobile services are supported through a unique 
public-private partnership with the SA insurance company First for 
Women. This enables our cervical cancer prevention services to be 
provided free of user fees.
Secondary analysis of programmatic data
Of the 25 public sector clinical sites supported by our programme, 
six were selected for enhanced monitoring and evaluation (M&E) 
activities. These sites, representing urban, periurban and rural areas 
of Gauteng and Mpumalanga, collect and report individual-level 
sociodemographic, HIV treatment and cervical cytology data for 
all women accessing Pap smear services. (Patient-level data are not 
available from the other 19 sites.)
In this report, we present the available data from these six 
enhanced M&E sites. Descriptive analysis included frequencies, 
measures of central tendency and measures of variability, which were 
generated for sociodemographic, clinical and laboratory variables. 
Considering only the index Pap smear, we report cytology results in 
accordance with the 2001 Bethesda System as no intraepithelial lesion 
or malignancy (NILM), atypical cells of undetermined significance 
(ASCUS), atypical glandular cells of undermined significance 
(AGUS), low-grade squamous intraepithelial lesion (LSIL), high-
grade SIL (HSIL), atypical squamous cells, cannot rule out a high-
grade lesion  (ASC-H), or suspicious for ICC.[13] We calculated the 
point estimates and corresponding 95% confidence intervals (CIs) for 
each of these cytological categories. We also examined the association 
between abnormal cytology (ASCUS or worse (ASCUS+), LSIL or 
worse (LSIL+), and HSIL or worse (HSIL+)) and both CD4+ cell 
count and receipt of antiretroviral therapy (ART). HIV-1 plasma viral 
load data were not available.
All data were cleaned using MS Excel, version 15.36 (Microsoft, 
USA) and then analysed using Stata version 12.1 (StataCorp, USA).
Conditional probability modelling to estimate the 
burden of cervical disease
First, we modelled the burden of cervical disease (i.e. abnormal 
histology) among the subset of women from our programme’s 
enhanced M&E sites (N=3 160). We used the frequencies of NILM, 
ASCUS, AGUS, LSIL, HSIL and cytology suspicious for ICC obtained 
from our programmatic database. We then estimated the expected 
number of NILM, cervical intraepithelial neoplasia grade 1 (CIN1), 
CIN grade 2 (CIN2), CIN grade 3 (CIN3), and ICC cases using the 
probability of observing each histological diagnosis conditional on 
each of the above cytological diagnoses. The histological (i.e. disease) 
probability estimates were obtained from a previous study conducted 
among HIV-infected women in Johannesburg.[12] Specifically, the 
probabilities of NILM, CIN1, CIN2, CIN3 and ICC were assumed 
to be 0.465, 0.482, 0.053, 0 and 0, respectively, among women with 
a NILM Pap smear; 0.103, 0.828, 0.069, 0 and 0, respectively, among 
women with an ASCUS Pap smear; 0.057, 0.803, 0.128, 0.012 and 0, 
respectively, among women with an LSIL Pap smear; 0.011, 0.313, 
0.408, 0.261 and 0.006, respectively, among women with an HSIL Pap 
smear; 0.103, 0.828, 0.069, 0 and 0, respectively, among women with 
an AGUS Pap smear; and 0, 0, 0, 0.500 and 0.500, respectively, among 
women with a Pap smear suspicious for ICC.
Second, we modelled the programme-wide burden of cervical 
disease, estimating the frequencies of NILM, CIN1, CIN2, CIN3 and 
ICC expected among all HIV-infected women accessing services 
through our programme (N=75 358) but for whom individual-
level information was not available. We used the probability of 
NILM, ASCUS, LSIL, ASC-H, HSIL and cytology suspicious for 
ICC observed in our programmatic database to model the expected 
frequency of each Pap smear finding. We then calculated the expected 
number of NILM, CIN1, CIN2, CIN3 and ICC cases using the 
parameter estimates from our published work,[12] as described above. 
Sensitivity analyses were conducted to provide low and high estimates 
of disease burden using the lower and upper bounds of the 95% CIs for 
NILM, ASCUS, LSIL, ASC-H, HSIL and cytology suspicious for ICC 
derived from programmatic data. Once again, we used a conditional 
probability modelling approach to determine low and high estimates 
of the number of cases of NILM, CIN1, CIN2, CIN3 and ICC.
All conditional probability models were created using MS Excel, 
version 15.36 (Microsoft, USA).
Ethical considerations
Ethical approval for secondary analysis of routine clinical data from 
the six clinical sites with enhanced M&E activities was obtained 
from the Human Research Ethics Committee, University of the 
Witwatersrand, Johannesburg (ref. no. M10956). All the women 
accessing services at these sites provided written informed consent 
for data collection.
Results
Between January 2009 and November 2015, 3 190 HIV-infected 
women accessed cervical screening services at a site from which 
individual-level data were available. Thirty women were excluded 
from the analysis because their Pap smear result was missing. The 
median age of the remaining 3 160 women was 37 years (interquartile 
range (IQR) 16 - 73). Most women had completed some secondary 
education (64.5%), and nearly half (47.8%) were employed. As 
expected, most women (77.9%) were receiving combination ART 
(cART), with a median CD4+ cell count of 348 cells/µL (IQR 208 - 
517) (Table 1).
Cytology results for the subset of 3 160 HIV-infected women are 
detailed in Table 1. Notably, 2 012 of these women (63.7%) had an 
ASCUS+ cytology result and 1 610 (50.9%) had an LSIL+ cytology 
result. Additionally, women with CD4+ cell counts ≤350 cells/µL 
were more likely to have an abnormal Pap smear than those with 
higher counts (p<0.001) (Table 2). However, receipt of cART did 
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not appear to decrease the risk of an abnormal Pap smear at the 
statistically significant level (data not shown).
In Tables 3 and 4, we provide estimates of the burden of cervical 
disease in both our analysis cohort and the programme at large. In 
the analysis cohort, consisting of 3 160 women, we estimate that there 
would have been 1 937 cases of CIN1 (61.3%) and 578 cases of CIN2+ 
(18.3%). Similarly, among 75 358 HIV-infected women we estimate 
that 27 355 would have had NILM, 9 570 ASCUS, 527 AGUS, 26 074 
LSIL and 11 605 HSIL Pap smears. We also estimate that 75 women 
would have had Pap smears suspicious for ICC. Conditional on 
these cytology results, we estimate 46 123 cases of CIN1 (range 
45 500 - 49 608) and 13 702 cases of CIN2+ (range 12 810 - 15 014), 
constituting an overwhelmingly high burden of disease.
Discussion
Sub-Saharan Africa is the global epicentre of the HIV epidemic: 70% 
of the 36.7 million people currently living with HIV are African, 
and 14.2 million are African women.[3] Although the introduction 
of cART has led to reductions in the incidence of cancers such 
as Kaposi’s sarcoma and non-Hodgkin’s lymphoma among HIV-
infected individuals,[14] the role of ART in reducing the incidence of 
ICC and its precursors remains unclear.[15] As increasing numbers of 
HIV-infected women initiate ART in places such as SA, we anticipate 
that longer life expectancy for these women will be coupled with a 
rising burden of chronic diseases, including ICC. [16,17]
Our model-based analysis indicates that nearly one in five HIV-
infected women in our programme will have been diagnosed with 
high-grade preinvasive cervical cancer requiring treatment with 
LEEP and close clinical follow-up to ensure that disease recurrence 
or progression is appropriately managed. Additionally, 61.3% of 
women were estimated to have CIN1, also requiring close clinical 
follow-up. Most strikingly, 104 cases of ICC were projected in this 
population, corresponding to a crude rate of 138 cases per 100 000 
women (range  81 - 247). This burden of ICC in HIV-infected 
women appears to be nearly five times the national age-standardised 
incidence of 32 per 100 000,[8] and is consistent with previous reports 
suggesting a two- to seven-fold increase in the risk of ICC among 
HIV-infected women.[18-20]
Our findings underscore how deeply neglected cancer prevention 
has been in settings such as SA, and raise concerns that high 
rates of ICC in HIV-infected women threaten to undo – or even 
reverse – gains in life expectancy achieved through HIV treatment 
programmes. Our results also suggest that continued advocacy and 
health service expansion are needed to improve cervical screening 
coverage. Below, we describe our service delivery model as an 
example that may be considered in similar settings.
Our cervical cancer prevention services are integrated into public 
sector HIV clinics to ensure that HIV-infected women can have full 
and timely access to cervical screening. Early in programme planning, 
we also recognised the far-reaching impact that constrained human 
resources can have on service delivery. To address the shortage 
of trained personnel, our team provides in-service training to 
DoH nurses and general medical officers. In the 6 years since our 
Table 1. Descriptive characteristics of programme 
participants from six selected clinics
Total, n (%)
Age (years), median (IQR) (N=3 160) 37 (16 - 73)
Education, n (%) (N=3 160)
No education 221 (7.0)
Primary education 765 (24.0)
Secondary education 2 037 (64.5)
Tertiary education 146 (4.6)
Employment, n (%) (N=3 160)
Yes 1 512 (47.8)
Cigarette smoking, n (%) (N=3 160)
Yes 80 (2.5)
Age at sexual debut, median (IQR) (N=3 156) 18 (17 - 24)
Parity, median (IQR) (N=3 160) 2 (1 - 3)
Hormonal contraception, n (%) (N=3 160)
None 2 448 (77.5)
Oral contraceptives 95 (3.0)
Injectables 600 (19.0)
Other 17 (0.5)
On antiretroviral therapy, n (%) (N=3 160)
Yes 2 460 (77.9)
CD4+ count (cells/µL), median (IQR)  
(N=3 137)
348 (208 - 517)
Cytology, n (%) (N=3 160)
NILM 1 148 (36.3)
ASCUS 402 (12.7)
AGUS 23 (0.7)
LSIL 1 094 (34.6)
HSIL 489 (15.5)
Suspicious for ICC 4 (0.1)
IQR = interquartile range; NILM = no intraepithelial lesion or malignancy; ASCUS = 
atypical cells of undetermined significance; AGUS = atypical glandular cells of 
undetermined significance; LSIL = low-grade squamous intraepithelial lesion; HSIL = 
high-grade intraepithelial lesion; ICC = invasive cervical cancer.
Table 2. Risk of abnormal cytology by CD4+ cell count
Total, N
CD4+ cell count  
≤350 cells/µL, n (%)
CD4+ cell count  
>350 cells/µL, n (%)
Using an ASCUS+ cutoff
NILM 1 140 428 (37.5) 712 (62.5)
ASCUS+ 1 997 1 161 (58.1) 836 (41.9)*
Using an LSIL+ cutoff
<LSIL 1 540 624 (40.5) 916 (59.5)
LSIL+ 1 597 965 (60.4) 632 (39.6)*
Using an HSIL+ cutoff
<HSIL 2 623 1 260 (48.0) 1 363 (52.0)
HSIL+ 514 329 (64.0) 185 (36.0)*
ASCUS+ = atypical cells of undetermined significance or worse; NILM = no intraepithelial lesion or malignancy; LSIL+ = low-grade squamous intraepithelial lesion or worse;  
HSIL+ = high-grade intraepithelial lesion or worse.
*p<0.001.
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screening programme was established, the annual number of Pap 
smears performed across the supported sites has increased by ~80% 
from 3 220 (in eight sites) to 18 791 (in 26 sites). We believe that our 
integrated model, coupled with training and mentorship support, has 
facilitated this expansion.
Additionally, an integrated model may help to circumvent the 
6 - 9-month waiting period for evaluation and treatment of pre-
invasive disease common in public gynaecology referral centres 
and may also reduce follow-up losses. Our decision to train medical 
officers (rather than specialist gynaecologists) has proved useful, 
Table 3. Estimated burden of histological disease among HIV-infected women for whom individual-level cytology data were 
available (N=3 160)
Estimated disease burden, n 
Cytology N NILM* CIN1* CIN2* CIN3* ICC†
NILM 1 148 534 554 60 0 0
ASCUS 402 42 333 28 0 0
AGUS 1 094 62 878 140 13 0
LSIL 489 6 153 200 128 3
HSIL 23 2 19 2 0 0
Suspicious for ICC 4 0 0 0 2 2
Total 3 160 646 1 937 430 143 5
NILM = no intraepithelial lesion or malignancy; ASCUS = atypical cells of undetermined significance; AGUS = atypical glandular cells of undetermined significance; LSIL = low-grade squamous 
intraepithelial lesion; HSIL = high-grade intraepithelial lesion; CIN = cervical intraepithelial neoplasia (grades 1, 2 and 3); ICC = invasive cervical cancer.
*Probabilities of NILM, CIN1, CIN2 and CIN3 for each cytological diagnosis are based on data previously published by our team.[12]
†Owing to the lack of robust data for HIV-infected women in our setting, probabilities of CIN3 and ICC are estimated as 0.500 for cytology results suspicious for ICC. 
Table 4. Estimated burden of histological disease among HIV-infected women accessing care through Right to Care’s Cervical 
Cancer Prevention Programme
Estimated disease burden, n 
Cytology Probability* N NILM† CIN1† CIN2† CIN3† ICC‡
Using the point 
estimates*
NILM 0.363 27 355 12 718 1 3198 1 440 0 0
ASCUS 0.127 9 570 990 7 920 660 0 0
AGUS 0.007 528 55 437 36 0 0
LSIL 0.346 26 074 1 486 20 933 3 344 310 0
HSIL 0.154 11 605 133 3 635 4 735 3 035 67
 Suspicious for 
ICC
0.001 75 0 0 0 38 38
Total 0.998 75 207 15 382 46 123 10 216 3 382‡ 104‡
Using the low 
estimates*
NILM 0.343 25 848 12 017 12 470 1 360 0 0
ASCUS 0.155 11 680 1 208 9 667 806 0 0
AGUS 0.005 377 39 312 26 0 0
LSIL 0.326 24 567 1 400 19 723 3 151 292 0
HSIL 0.141 10 625 122 3 328 4 336 2 779 61
 Suspicious for 
ICC
0 0 0 0 0 0 0
Total 0.970 73 097 14 787 45 500 9 679 3 070 61
Using the high 
estimates*
NILM 0.385 29 013 13 488 13 997 1 527 0 0
ASCUS 0.140 10 550 1 091 8 731 728 0 0
AGUS 0.011 829 86 686 57 0 0
LSIL 0.367 27 656 1 577 22 204 3 547 328 0
HSIL 0.169 12 736 146 3 989 5 197 3 330 73
 Suspicious for 
ICC
0.003 226 0 0 0 113 113
Total 1.075 81 010 16 389 49 608 11 056 3 772 186
NILM = no intraepithelial lesion or malignancy; ASCUS = atypical cells of undetermined significance; AGUS = atypical glandular cells of undetermined significance; LSIL = low-grade squamous 
intraepithelial lesion; HSIL = high-grade intraepithelial lesion; CIN = cervical intraepithelial neoplasia (grades 1, 2 and 3); ICC = invasive cervical cancer.
*Probabilities for the distribution of cytology results determined using data shown in Table 3, with the low estimate representing the lower 95% confidence bound and the high estimate the upper 
95% confidence bound.
†Probabilities of NILM, CIN1, CIN2 and CIN3 for each cytological diagnosis are based on data previously published by our team.[12]
‡Owing to the lack of robust data for HIV-infected women in our setting, probabilities of CIN3 and ICC are estimated as 0.500 for cytology results suspicious for ICC.
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particularly at lower-level health facilities, where women can 
now undergo cervical colposcopy (evaluating abnormal cytology 
results through magnification of the cervix and guided biopsy) 
and treatment for preinvasive cervical disease. Mobile units (see 
‘Methods’) have also extended a broad range of reproductive health 
services to under-served areas and are an integral component of 
our programme.
Despite the rapid expansion of our service delivery model, overall 
access to cervical screening and prevention and treatment of ICC 
in SA remains suboptimal. We also acknowledge the challenges of 
integrated service delivery models, including numerous ways in 
which integration may stretch the capacity of individual clinicians. 
Additionally, our service delivery approach would not be relevant 
for HIV-uninfected women, for whom different strategies may 
be required (e.g. integration of cervical screening services within 
antenatal and/or postnatal care). Furthermore, we note several 
limitations of our model-based analysis. First, our model is based 
on data obtained primarily from urban and periurban clinical sites, 
which may not be fully representative of rural settings. Second, 
although we have provided low and high estimates (based on 95% 
CIs) of the burden of disease to account for the uncertainty in our 
point estimates, the number of cases of ICC in our analysis dataset 
was low, leading to wide confidence bands and large ranges in the 
model estimates for ICC. Finally, our model-based analysis does not 
account for attrition from care, and we have not estimated the cost or 
cost-effectiveness of the integrated approach.
Conclusion
We estimate that among ~75 000 HIV-infected women, there were 
46 123 cases of CIN1 and 13 702 cases of CIN2+, confirming a high 
burden of cervical disease in this population, where nearly one in 
five women was thought to have high-grade, preinvasive disease 
and more than 100 cases of ICC were estimated. We also describe 
an integrated service delivery model that, if expanded, may provide 
greater and more equitable access to cervical cancer prevention for 
HIV-infected women in SA. Cervical cancer incidence is projected 
to rise in LMICs in the coming decade, particularly in countries 
with a high burden of HIV. Public sector programmes that rapidly 
increase screening coverage, strengthen linkages between screening 
and treatment, and improve treatment outcomes for this preventable 
cancer are urgently needed.
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